Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.

In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.

Administering 1.0 mg of Semaglutide led to a 24% decrease in occurrences related to kidney disease among individuals with type 2 diabetes and persistent kidney conditions.

Codeine, a diminutive molecular compound, exerts its agonistic influence upon opioid receptors situated within the central nervous system.

Gilead Sciences and Merck unveil preliminary results from stage two trial revealing that a weekly oral blend of Islatravir and Lenacapavir successfully sustained control over viral levels up to the 24-week mark.

Islet Amyloid Polypeptide (IAPP), also known as amylin, is a peptide hormone composed of 37 amino acids, secreted by the pancreatic beta-cells.

Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.

Clotrimazole, a diminutive molecule of pharmacological relevance, exerts its influence as an astoundingly powerful CYP51A1 inhibitor.

Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.

AbbVie, a US-based pharma company, partnered with French firm OSE Immunotherapeutics on Feb 28 to co-develop OSE-230, a new monoclonal antibody for chronic inflammation.

LAVA has reported progress in clinical phase achievements by Pfizer with the drug PF-08046052, previously known as SGN-EGFRd2 or LAVA-1223.

Estradiol (E2), a predominant female sex hormone and a member of the estrogen family, is responsible for regulating the menstrual and estrous cycles.